PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer

Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron emission tomography (PET)/computed tomography (CT) adds precise anatomical localisation to functional data. The use of PET/CT may add further value to the diagnosis and staging of pancreatic cancer. To determine...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Health technology assessment (Winchester, England) England), 2018-02, Vol.22 (7), p.1-114
Hauptverfasser: Ghaneh, Paula, Hanson, Robert, Titman, Andrew, Lancaster, Gill, Plumpton, Catrin, Lloyd-Williams, Huw, Yeo, Seow Tien, Edwards, Rhiannon Tudor, Johnson, Colin, Abu Hilal, Mohammed, Higginson, Antony P, Armstrong, Tom, Smith, Andrew, Scarsbrook, Andrew, McKay, Colin, Carter, Ross, Sutcliffe, Robert P, Bramhall, Simon, Kocher, Hemant M, Cunningham, David, Pereira, Stephen P, Davidson, Brian, Chang, David, Khan, Saboor, Zealley, Ian, Sarker, Debashis, Al Sarireh, Bilal, Charnley, Richard, Lobo, Dileep, Nicolson, Marianne, Halloran, Christopher, Raraty, Michael, Sutton, Robert, Vinjamuri, Sobhan, Evans, Jonathan, Campbell, Fiona, Deeks, Jon, Sanghera, Bal, Wong, Wai-Lup, Neoptolemos, John P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pancreatic cancer diagnosis and staging can be difficult in 10-20% of patients. Positron emission tomography (PET)/computed tomography (CT) adds precise anatomical localisation to functional data. The use of PET/CT may add further value to the diagnosis and staging of pancreatic cancer. To determine the incremental diagnostic accuracy and impact of PET/CT in addition to standard diagnostic work-up in patients with suspected pancreatic cancer. A multicentre prospective diagnostic accuracy and clinical value study of PET/CT in suspected pancreatic malignancy. Patients with suspected pancreatic malignancy. All patients to undergo PET/CT following standard diagnostic work-up. The primary outcome was the incremental diagnostic value of PET/CT in addition to standard diagnostic work-up with multidetector computed tomography (MDCT). Secondary outcomes were (1) changes in patients' diagnosis, staging and management as a result of PET/CT; (2) changes in the costs and effectiveness of patient management as a result of PET/CT; (3) the incremental diagnostic value of PET/CT in chronic pancreatitis; (4) the identification of groups of patients who would benefit most from PET/CT; and (5) the incremental diagnostic value of PET/CT in other pancreatic tumours. Between 2011 and 2013, 589 patients with suspected pancreatic cancer underwent MDCT and PET/CT, with 550 patients having complete data and in-range PET/CT. Sensitivity and specificity for the diagnosis of pancreatic cancer were 88.5% and 70.6%, respectively, for MDCT and 92.7% and 75.8%, respectively, for PET/CT. The maximum standardised uptake value (SUV ) for a pancreatic cancer diagnosis was 7.5. PET/CT demonstrated a significant improvement in relative sensitivity (  = 0.01) and specificity (  = 0.023) compared with MDCT. Incremental likelihood ratios demonstrated that PET/CT significantly improved diagnostic accuracy in all scenarios (  
ISSN:1366-5278
2046-4924
DOI:10.3310/hta22070